InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or
the “Company”), a leading national health care service provider,
facilitating outpatient care for durable medical equipment
manufacturers and health care providers, announced today a
three-year distribution agreement with Smith+Nephew for its
innovative negative pressure wound therapy (“NPWT”) system and
supplies.
Under this agreement, InfuSystem will offer Smith+Nephew’s
advanced RENASYS◊ EDGE negative pressure wound therapy
system, an exciting new option in home-based care for patients
living with chronic wounds. The RENASYS EDGE system is lightweight
and compact allowing it to be easily carried or worn, featuring a
discreet canister and operates quietly to not draw attention or
disturb the patients’ daily activities.
Richard DiIorio, Chief Executive Officer of InfuSystem, said,
“Based on our more than 800 in-network health insurance providers
covering over 96% of the U.S. population and our well-established
and trusted service capabilities, Smith+Nephew approached
InfuSystem to assist them as a secondary distribution partner for
their RENASYS EDGE system. We are excited about this new
partnership, that will leverage InfuSystem’s unique Patient
Services platform to deliver customized solutions. InfuSystem’s
ability to wrap its high-value services around our partners’
products will quickly benefit and attract new revenue opportunities
for both companies and more importantly giving more patients
increased access to the new RENASYS EDGE technology.”
About Smith+Nephew
Smith+Nephew is a portfolio medical technology company focused
on the repair, regeneration and replacement of soft and hard
tissue. We exist to restore people’s bodies and their self-belief
by using technology to take the limits off living. We call this
purpose “Life Unlimited”. Our 18,000 employees deliver this mission
every day, making a difference to patients’ lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global franchises
of Orthopaedics, Sports Medicine & ENT and Advanced Wound
Management. Founded in Hull, UK, in 1856, we now operate in more
than 100 countries, and generated annual sales of $5.2 billion in
2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). The terms “Group” and “Smith+Nephew” are used to refer
to Smith & Nephew plc and its consolidated subsidiaries, unless
the context requires otherwise.
For more information about Smith+Nephew, please visit
www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram
or Facebook.
◊ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading
national health care service provider, facilitating outpatient care
for durable medical equipment manufacturers and health care
providers. INFU services are provided under a two-platform model.
The first platform is Patient Services, providing the last-mile
solution for clinic-to-home healthcare where the continuing
treatment involves complex durable medical equipment and services.
The Patient Services segment is comprised of Oncology, Pain
Management and Wound Therapy businesses. The second platform,
Device Solutions, supports the Patient Services platform and
leverages strong service orientation to win incremental business
from its direct payer clients. The Device Solutions segment is
comprised of direct payer rentals, pump and consumable sales, and
biomedical services. Headquartered in Rochester Hills, Michigan,
the Company delivers local, field-based customer support and also
operates Centers of Excellence in Michigan, Kansas, California,
Massachusetts, Texas and Ontario, Canada.
Forward-Looking Statements
Certain statements contained in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, such as statements
relating to future actions, our share repurchase program and
capital allocation strategy, business plans, strategic
partnerships, growth initiatives, objectives and prospects, future
operating or financial performance, guidance and expected new
business relationships and the terms thereof (including estimated
potential revenue under new or existing contracts). The words
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “should,” “plan,” “goal,” “expect,” “strategy,” “future,”
“likely,” variations of such words, and other similar expressions,
as they relate to the Company, are intended to identify
forward-looking statements. Forward-looking statements are subject
to factors, risks and uncertainties that could cause actual results
to differ materially, including, but not limited to, our ability to
successfully execute on our growth initiatives and strategic
partnerships, our ability to enter into definitive agreements for
the new business relationships on expected terms or at all, our
ability to generate estimated potential revenue amounts under new
or existing contracts, our dependence on estimates of collectible
revenue, potential litigation, changes in third-party reimbursement
processes, changes in law, global financial conditions and
recessionary risks, rising inflation and interest rates, supply
chain disruptions, systemic pressures in the banking sector,
including disruptions to credit markets, the Company's ability to
remediate its previously disclosed material weaknesses in internal
control over financial reporting, contributions from acquired
businesses or new business lines, products or services and other
risk factors disclosed in the Company’s most recent annual report
on Form 10-K and, to the extent applicable, quarterly reports on
Form 10-Q. Our strategic partnerships are subject to similar
factors, risks and uncertainties. All forward-looking statements
made in this press release speak only as of the date hereof. We do
not undertake any obligation to update any forward-looking
statements to reflect future events or circumstances, except as
required by law.
Additional information about InfuSystem Holdings, Inc. is
available at www.infusystem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240806221232/en/
Joe Dorame, Joe Diaz & Robert Blum Lytham Partners, LLC
602-889-9700
InfuSystems (AMEX:INFU)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
InfuSystems (AMEX:INFU)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
